Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) - Net Assets
Based on the latest financial reports, Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) has net assets worth CN¥1.27 Billion CNY (≈ $185.51 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.30 Billion ≈ $336.59 Million USD) and total liabilities (CN¥1.03 Billion ≈ $151.08 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Beijing Sun Novo Pharmaceutical Research (688621) tangible net worth to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.27 Billion |
| % of Total Assets | 55.11% |
| Annual Growth Rate | 57.1% |
| 5-Year Change | 60.27% |
| 10-Year Change | N/A |
| Growth Volatility | 92.45 |
Beijing Sun Novo Pharmaceutical Research Co Ltd - Net Assets Trend (2017–2025)
This chart illustrates how Beijing Sun Novo Pharmaceutical Research Co Ltd's net assets have evolved over time, based on quarterly financial data. See defensive interval ratio of Beijing Sun Novo Pharmaceutical Research to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Beijing Sun Novo Pharmaceutical Research Co Ltd (2017–2025)
The table below shows the annual net assets of Beijing Sun Novo Pharmaceutical Research Co Ltd from 2017 to 2025. For live valuation and market cap data, see Beijing Sun Novo Pharmaceutical Research (688621) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.23 Billion ≈ $180.50 Million |
+11.87% |
| 2024-12-31 | CN¥1.10 Billion ≈ $161.35 Million |
+4.29% |
| 2023-12-31 | CN¥1.06 Billion ≈ $154.71 Million |
+16.41% |
| 2022-12-31 | CN¥908.23 Million ≈ $132.90 Million |
+18.01% |
| 2021-12-31 | CN¥769.64 Million ≈ $112.62 Million |
+298.95% |
| 2020-12-31 | CN¥192.92 Million ≈ $28.23 Million |
+62.45% |
| 2019-12-31 | CN¥118.76 Million ≈ $17.38 Million |
+60.87% |
| 2018-12-31 | CN¥73.82 Million ≈ $10.80 Million |
+122.01% |
| 2017-12-31 | CN¥33.25 Million ≈ $4.87 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Beijing Sun Novo Pharmaceutical Research Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 8300.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥742.83 Million | 61.02% |
| Other Components | CN¥474.54 Million | 38.98% |
| Total Equity | CN¥1.22 Billion | 100.00% |
Beijing Sun Novo Pharmaceutical Research Co Ltd Competitors by Market Cap
The table below lists competitors of Beijing Sun Novo Pharmaceutical Research Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
China West Construction Group Co Ltd
SHE:002302
|
$858.96 Million |
|
GL Events SA
PA:GLO
|
$859.42 Million |
|
Prashkovsky
TA:PRSK
|
$859.87 Million |
|
Opko Health Inc
NASDAQ:OPK
|
$860.81 Million |
|
Exmar NV
BR:EXM
|
$858.77 Million |
|
Zhejiang Tiantie Industry Co Ltd
SHE:300587
|
$858.70 Million |
|
Ratos AB (publ)
ST:RATO-B
|
$858.42 Million |
|
Kunming Chuan Jin Nuo Chemical Co Ltd
SHE:300505
|
$858.33 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Beijing Sun Novo Pharmaceutical Research Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,100,637,054 to 1,217,372,673, a change of 116,735,619 (10.6%).
- Net income of 196,083,300 contributed positively to equity growth.
- Dividend payments of 32,260,825 reduced retained earnings.
- Other factors decreased equity by 47,086,856.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥196.08 Million | +16.11% |
| Dividends Paid | CN¥32.26 Million | -2.65% |
| Other Changes | CN¥-47.09 Million | -3.87% |
| Total Change | CN¥- | 10.61% |
Book Value vs Market Value Analysis
This analysis compares Beijing Sun Novo Pharmaceutical Research Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.72x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 141.97x to 4.72x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥0.37 | CN¥52.40 | x |
| 2018-12-31 | CN¥0.91 | CN¥52.40 | x |
| 2019-12-31 | CN¥1.39 | CN¥52.40 | x |
| 2020-12-31 | CN¥2.26 | CN¥52.40 | x |
| 2021-12-31 | CN¥7.78 | CN¥52.40 | x |
| 2022-12-31 | CN¥8.02 | CN¥52.40 | x |
| 2023-12-31 | CN¥9.29 | CN¥52.40 | x |
| 2024-12-31 | CN¥9.80 | CN¥52.40 | x |
| 2025-12-31 | CN¥11.11 | CN¥52.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Beijing Sun Novo Pharmaceutical Research Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 16.11%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.10%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 1.88x
- Recent ROE (16.11%) is below the historical average (21.51%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 5.81% | 5.49% | 0.33x | 3.23x | CN¥-1.43 Million |
| 2018 | 27.54% | 15.37% | 0.67x | 2.68x | CN¥13.19 Million |
| 2019 | 40.64% | 20.30% | 0.82x | 2.45x | CN¥35.74 Million |
| 2020 | 38.32% | 20.86% | 0.90x | 2.04x | CN¥53.55 Million |
| 2021 | 13.87% | 21.40% | 0.40x | 1.63x | CN¥29.47 Million |
| 2022 | 17.45% | 23.13% | 0.46x | 1.63x | CN¥66.80 Million |
| 2023 | 17.76% | 19.82% | 0.50x | 1.79x | CN¥80.76 Million |
| 2024 | 16.12% | 16.45% | 0.54x | 1.81x | CN¥67.35 Million |
| 2025 | 16.11% | 16.10% | 0.53x | 1.88x | CN¥74.35 Million |
Industry Comparison
This section compares Beijing Sun Novo Pharmaceutical Research Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,041,443,343
- Average return on equity (ROE) among peers: 10.73%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) | CN¥1.27 Billion | 5.81% | 0.81x | $858.79 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $971.04 Million | 5.41% | 3.98x | $565.97 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.33 Billion | 6.10% | 1.68x | $359.03 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $8.39 Billion | 22.09% | 0.19x | $4.30 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $3.01 Billion | 11.93% | 0.53x | $2.52 Billion |
| Wedge Industrial Co Ltd (000534) | $1.15 Billion | 11.42% | 1.59x | $2.41 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $1.42 Billion | 23.64% | 1.01x | $12.64 Billion |
| Hainan Haiyao Co Ltd (000566) | $445.29 Million | 14.73% | 0.90x | $715.72 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $347.80 Million | 3.58% | 0.72x | $319.94 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $905.53 Million | 2.15% | 1.95x | $916.75 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $22.44 Billion | 6.25% | 0.15x | $3.00 Billion |
About Beijing Sun Novo Pharmaceutical Research Co Ltd
Beijing Sun-Novo Pharmaceutical Research Co., Ltd., a contract research company, engages in the research and development of drugs in China. The company operates external preparation platform that focuses on the research and development of new drugs and generic drugs for skin external preparations; children's clinical data bridging research center; pediatric drug research and development platform;… Read more